Eplerenone
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1892 publications
Can we differentiate between finerenone, eplerenone and spironolactone in HFmrEF/HFpEF through a Bayesian lens?
Journal: European journal of heart failure
Published: March 22, 2026
Real-World Benefit of Spironolactone and Eplerenone in HFpEF: Evidence From a Large-Scale Observational Study.
Journal: American journal of therapeutics
Published: March 17, 2026
Human 3D Cardiac Microtissue Model to Investigate Aldosterone-Induced Fibrosis and Electrical Dysfunction.
Journal: Hypertension (Dallas, Tex. : 1979)
Published: March 16, 2026
The Pharmacological Properties and Safety Profile of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction.
Journal: The Journal of the Association of Physicians of India
Published: March 12, 2026
Risk of Delaying or Omitting Mineralocorticoid Receptor Antagonists in Heart Failure.
Journal: The Journal of the Association of Physicians of India
Published: March 12, 2026
Mineralocorticoid Receptor Antagonists: An Overview of History and Evolution.
Journal: The Journal of the Association of Physicians of India
Published: March 12, 2026
Mineralocorticoid Receptor Antagonists: The Pillar Drug in Heart Failure.
Journal: The Journal of the Association of Physicians of India
Published: March 12, 2026
Diurnal rhythm in blood pressure is preserved in hypertensive mice despite therapy with mineralocorticoid receptor antagonists.
Journal: Journal of cardiovascular pharmacology
Published: February 27, 2026
Comparative Effectiveness of Mineralocorticoid Receptor Antagonists in Cardiovascular, Renal and Metabolic Disease.
Journal: Current problems in cardiology
Published: February 24, 2026
Effects of mineralocorticoid receptor antagonists on cardiometabolic profile and liver health in individuals with increased cardiometabolic risk: a systematic review and meta-analysis of randomized controlled trials.
Journal: Expert review of cardiovascular therapy
Published: February 17, 2026
Central Serous Chorioretinopathy: Etiology, Diagnosis, and Treatment.
Journal: Deutsches Arzteblatt international
Published: February 12, 2026
Tspan4+ fibroblasts facilitate the development of NECSO in myocardial ischemia reperfusion through migrasomes-mediated Tnf-α autocrine and cardiomyocytes aldosterone generation.
Journal: Biochemical pharmacology
Published: January 23, 2026
Last Updated: 04/28/2026